Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 4/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661168 | 0.97 | QPCT (0.52) | QPCTGSK3B | |
| SCHEMBL16366868 | 0.80 | MAPT (0.40) | — | |
| SCHEMBL14012429 | 0.78 | QPCT (0.48) | QPCTGSK3B | |
| SCHEMBL6790333 | 0.77 | TDP1 (0.71) | TDP1L3MBTL1 | |
| SCHEMBL1786505 | 0.75 | HSD17B10 (0.46) | TDP1L3MBTL1 | |
| SCHEMBL2604742 | 0.75 | TDP1 (0.75) | TDP1L3MBTL1 | |
| SCHEMBL8862728 | 0.75 | TDP1 (0.75) | TDP1L3MBTL1 | |
| SCHEMBL8862878 | 0.75 | TDP1 (0.75) | TDP1L3MBTL1 | |
| SCHEMBL6777483 | 0.75 | TDP1 (0.75) | TDP1L3MBTL1 | |
| SCHEMBL8863154 | 0.75 | TDP1 (0.75) | TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| EP-2865670-A1 | Thiourea derivatives as glutaminyl cyclase inhibitors | Probiodrug AG (DE) | 2015-04-29 | — | — | EP | disclosed |
| EP-2142514-B1 | THIOUREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-12-24 | — | — | EP | disclosed |
| US-8772508-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2014-07-08 | — | — | US | disclosed |
| EP-2142513-B1 | NITROVINYL-DIAMINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-2142513-A1 | NITROVINYL-DIAMINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2010-01-13 | — | — | EP | disclosed |
| EP-2142514-A1 | THIOUREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2010-01-13 | — | — | EP | disclosed |
| US-20080292582-A1 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | PROBIODRUG AG (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-11-20 | — | — | US | disclosed |
| WO-2008128981-A1 | NITROVINYL-DIAMINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128985-A1 | THIOUREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292582-A1 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | HTT, MAPT, HYPK | QPCT 4555/4885GSK3B 1222/4885TDP1 72/4885 |
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | QPCT 3/4885GSK3B 785/4885TDP1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.